Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guerin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance

Oddens, Jorg; Brausi, Maurizio; Sylvester, Richard; Bono, Aldo; van de Beek, Cees; van Andel, George; Gontero, Paolo; Hoeltl, Wolfgang; Turkeri, LEVENT; Marreaud, Sandrine; Collette, Sandra; Oosterlinck, Willem

doi:10.1016/j.eururo.2012.10.039

Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guerin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance

Atıf İçin Kopyala

Oddens J., Brausi M., Sylvester R., Bono A., van de Beek C., van Andel G., ...Daha Fazla

EUROPEAN UROLOGY, cilt.63, sa.3, ss.462-472, 2013 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 63 Sayı: 3
Basım Tarihi: 2013
Doi Numarası: 10.1016/j.eururo.2012.10.039
Dergi Adı: EUROPEAN UROLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.462-472
Anahtar Kelimeler: Non-muscle invasive bladder cancer, Randomized Controlled Trial, Immunotherapy, Bacillus Calmette-Guerin, Adjuvant treatment, Urinary bladder, Maintenance therapy, TRANSITIONAL-CELL CARCINOMA, TRANSURETHRAL RESECTION, UROTHELIAL CARCINOMA, MITOMYCIN-C, FOLLOW-UP, 27 MG, TRIAL, TUMORS, PROGRESSION, EFFICACY
Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

Background: The optimal dose and duration of intravesical bacillus Calmette-Guerin (BCG) in the treatment of non-muscle-invasive bladder cancer (NMIBC) are controversial.